SC 13G

NAME OF REPORTING PERSON

Norwest Venture Partners XIV, LP

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐ (b) ☐

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

SC 13G 1 d186227dsc13g.htm SC 13G SC 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. __)*

Impel NeuroPharma, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

45258K109

(CUSIP Number)

June 30, 2021

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

13G

CUSIP NO. 45258K109

13G

CUSIP NO. 45258K109

13G

CUSIP NO. 45258K109

13G

CUSIP NO. 45258K109

13G

CUSIP NO. 45258K109

13G

CUSIP NO. 45258K109

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

Item 1(a)

Name of Issuer:

Impel NeuroPharma, Inc.

Item 1(b)

Address of Issuer’s Principal Executive Offices:

915 East Pine Street

Suite 401

Seattle, WA 98122

Item 2(a)

Name of Person Filing:

Norwest Venture Partners XIV, LP

Genesis VC Partners XIV, LLC

NVP Associates, LLC

Promod Haque

Jeffrey Crowe

Jon E. Kossow

Item 2(b)

Address of Principal Business Office or, if None, Residence:

Norwest Venture Partners XIV, LP

525 University Ave, Suite 800

Palo Alto, CA 94301

Genesis VC Partners XIV, LLC

525 University Ave, Suite 800

Palo Alto, CA 94301

NVP Associates, LLC

525 University Ave, Suite 800

Palo Alto, CA 94301

Promod Haque

525 University Ave, Suite 800

Palo Alto, CA 94301

Jeffrey Crowe

525 University Ave, Suite 800

Palo Alto, CA 94301

Jon E. Kossow

525 University Ave, Suite 800

Palo Alto, CA 94301

This statement is filed by Norwest Venture Partners XIV, LP on behalf of all of the persons listed above pursuant to Rule 13d-1(d) and Rule 13d-1(k). Norwest Venture Partners XIV, LP is a Delaware limited partnership, whose general partner is Genesis VC Partners XIV, LLC. NVP Associates, LLC is the managing member of Genesis VC Partners XIV, LLC. Promod Haque, Jeffrey Crowe and Jon E. Kossow are co-Chief Executive Officers of NVP Associates, LLC.

Item 2(c)

Citizenship:

Norwest Venture Partners XIV, LP: Delaware

Genesis VC Partners XIV, LLC: Delaware

NVP Associates, LLC: Delaware

Promod Haque: United States of America

Jeffrey Crowe: United States of America

Jon E. Kossow: United States of America

Item 2(d)

Title of Class of Securities:

Common Stock

Item 2(e)

CUSIP Number:

45258K109

Item 3

Not Applicable

Item 4

Ownership:

(1) Norwest Venture Partners XIV, LP (“NVP XIV”): At June 30, 2021, NVP XIV owned of record 3,077,198 shares of Issuer’s common stock (“Common Stock”). This amount represents 13.81% of the total shares of Common Stock outstanding at this date.

(2) Genesis VC Partners XIV, LLC (“Genesis XIV”): At June 30, 2021, Genesis XIV may be deemed to have beneficially owned, by virtue of its status as general partner of NVP XIV, 3,077,198 shares of Common Stock. This amount represents 13.81% of the total shares of Common Stock outstanding at this date.

(3) NVP Associates, LLC (“NVP Associates”): At June 30, 2021, NVP Associates may be deemed to have beneficially owned 3,077,198 shares of Common Stock by virtue of its status as managing member of Genesis XIV, the general partner of NVP XIV, the record owner of such shares. This amount represents 13.81% of the total shares of Common Stock outstanding at this date.

(4) Promod Haque: At June 30, 2021, Promod Haque may be deemed to have beneficially owned 3,077,198 shares of Common Stock by virtue of his status as co-Chief Executive Officer of NVP Associates, the managing member of Genesis XIV, which is the general partner of NVP XIV, the record owner of such shares. This amount represents 13.81% of the total shares of Common Stock outstanding at this date.

(5) Jeffrey Crowe: At June 30, 2021, Jeffrey Crowe may be deemed to have beneficially owned 3,077,198 shares of Common Stock by virtue of his status as co-Chief Executive Officer of NVP Associates, the managing member of Genesis XIV, which is the general partner of NVP XIV, the record owner of such shares. This amount represents 13.81% of the total shares of Common Stock outstanding at this date.

(6) Jon E. Kossow: At June 30, 2021, Jon E. Kossow may be deemed to have beneficially owned 3,077,198 shares of Common Stock by virtue of his status as co-Chief Executive Officer of NVP Associates, the managing member of Genesis XIV, which is the general partner of NVP XIV, the record owner of such shares. This amount represents 13.81% of the total shares of Common Stock outstanding at this date.

Item 5

Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting persons have ceased to be beneficial owners of more than five percent of the class of securities, check the following [ ].

Item 6

Ownership of More than Five Percent on Behalf of Another Person:

Not Applicable

Item 7

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

Not Applicable

Item 8

Identification and Classification of Members of the Group:

Not Applicable

Item 9

Notice of Dissolution of Group:

Not Applicable

Item 10

Certification:

Not applicable

Signature.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

Date: August 9, 2021


NORWEST VENTURE PARTNERS XIV, LP

By Genesis VC Partners XIV, LLC, as general partner
By NVP Associates, LLC, as managing member

By:		/s/ Matthew De Dominicis
		Matthew De Dominicis, Chief Financial Officer

AGREEMENT

The undersigned hereby agree that this Schedule 13G to which this Agreement is attached shall be filed by Norwest Venture Partners XIV, LP on its own behalf and on behalf of (a) Genesis VC Partners XIV, LLC, a Delaware limited liability company, (b) NVP Associates, LLC, a Delaware limited liability company, (c) Promod Haque, (d) Jeffrey Crowe and (e) Jon E. Kossow.

Dated: August 9, 2021


Norwest Venture Partners XIV, LP

By Genesis VC Partners XIV, LLC, as general partner
By NVP Associates, LLC, as managing member

By:		/s/ Matthew De Dominicis
		Matthew De Dominicis, Chief Financial Officer

Genesis VC Partners XIV, LLC
By NVP Associates, LLC, as managing member

By:		/s/ Matthew De Dominicis
		Matthew De Dominicis, Chief Financial Officer

NVP Associates, LLC

By:		/s/ Matthew De Dominicis
		Matthew De Dominicis, Chief Financial Officer

/s/ Matthew De Dominicis
Matthew De Dominicis, as Attorney-in-fact for Promod Haque

/s/ Matthew De Dominicis
Matthew De Dominicis, as Attorney-in-fact for Jeffrey Crowe

/s/ Matthew De Dominicis
Matthew De Dominicis, as Attorney-in-fact for Jon E. Kossow

SEC Form SC 13G filed by Impel NeuroPharma Inc.